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Abstract 
Sarah E. Krier, PhD, MPH 
Challenges in Efforts to Control Yellow Fever Outbreaks in Brazil Since 2016:  
A Literature Review 
Elizabeth Marie Owens, MPH 
University of Pittsburgh, 2019 
Abstract 
Yellow fever is a vector-borne disease transmitted to humans and non-human primates 
through the bite of an infected mosquito. The disease is preventable with a live-attenuated vaccine, 
which is considered safe, effective, and provides lifelong immunity. Since 2016, Brazil has 
experienced an influx of Yellow fever outbreaks throughout the country due to the expansion of 
the virus.  This literature review examines factors contributing to the expansion of Yellow fever 
throughout Brazil and identifies challenges to Yellow fever prevention and control efforts ongoing 
throughout the country. A systematic literature search was conducted, and twenty-nine relevant 
articles were found to meet the selection criteria of Yellow fever, Brazil, challenges, and 
population health. This review of literature revealed lack of Yellow fever immunity, adverse 
effects of vaccination, deforestation, fractional dosing, and various vaccine supply chain 
challenges to be the leading challenges facing the Yellow fever control efforts in Brazil since 2016. 
In the interest of public health, these findings are significant because they have shown that 
initiating additional prevention methods and revising policies in turn could exceedingly end the 
Yellow fever epidemic in Brazil, while simultaneously reducing morbidity and mortality of this 
vaccine-preventable disease. 
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1.0 Introduction 
Yellow fever (YF) is a vector-borne disease caused by a Flavivirus that is endemic 
throughout tropical and subtropical regions of Africa, Central America and South America.  
Throughout history, YF has caused numerous epidemics with high mortality.  The World Health 
Organization (WHO) currently reports an average of 200,000 cases with 30,000 deaths per year 
(Staples, Gershman, Fischer, & Centers for Disease Control and Prevention, 2010).  The official 
number of reported cases are far lower than projected numbers, due to the geographic spread of 
the disease and inadequate surveillance and reporting.  
Brazil has been experienced many YF outbreaks in both endemic and non-endemic regions 
throughout the country. Over the course of the past two decades, the number of YF cases 
worldwide have increased, particularly within Brazil. Since 2016, the Brazilian Ministry of Health 
has confirmed 2,229 human cases of YF with 763 deaths (“WHO | Yellow fever – Brazil”). Current 
vaccination coverage in Brazil is less than the WHO recommendation of 80%, which puts greater 
risk for YF transmission throughout the country (Klitting, Gould, Paupy, & de Lamballerie, 2018). 
This literature review examines factors contributing to Yellow fever outbreaks and identifies 
challenges in YF prevention and control efforts in Brazil since 2016. Furthermore, this literature 
review offers strategies to help guide public health officials and government leaders on the 
necessary changes to address and control the YF epidemic in Brazil. 
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1.1 Fever Transmission 
YF infects both humans and non-human primates (NHPs) through the bite of an infected 
female mosquito. Increased temperature, humidity, and rainfall lead to higher mosquito abundance 
and consequently an increase in YF circulation throughout Africa and South America (Staples, 
Gershman, Fischer, & Centers for Disease Control and Prevention, 2010). Specifically, in South 
America, YF follows a seasonal pattern with highest incidence rates and vector density from 
January to May (Monath & Cetron, 2002). These mosquito species live and breed in different 
habitats, thus producing three different types of YF transmission cycles.   
The first cycle, known as sylvatic, transmits in jungles or tropical rainforests.  Monkeys 
are the primary reservoir from infected Haemogous or Sabethes mosquitoes and the YF virus 
passes on to other monkeys and occasionally humans who work or travel to these remote locations.  
The second cycle, known as intermediate, encompasses semi-domestic mosquitoes that breed both 
in the wild and around households. Increased contact between people and infected mosquitoes 
create outbreaks amongst neighboring villages and communities. The third transmission cycle, 
known as domestic, occurs in urban settings by infected Ae. aegypti mosquitoes through person-
to-person transmission. Urban settings are vulnerable to create endemic outbreaks, not only 
because of high population and mosquito density, but also due to the lack of vector control and 
low immunization rates (Cupertino et al., 2019). 
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1.2 Yellow Fever Clinical Presentation 
YF is an acute, non-contagious viral hemorrhagic disease that can cause mild, severe, and 
fatal effects. The incubation period varies between three to six days from initial infection.  Signs 
and symptoms include fever, muscle pain, headache, loss of appetite, nausea and vomiting. With 
no cure, the primary treatment is supportive care with intravenous hydration, fever reducers, and 
rest. About 15% of those infected progress to a more toxic phase from initial symptoms, effecting 
both the liver and kidneys and usually die within 7 to 10 days.  Infected patients will develop 
yellowish coloring of the skin and eyes, known as jaundice, due to inflammation of the liver and 
dying liver cells that are unable to secrete bilirubin through the gallbladder (Cupertino et al., 2019). 
South America has a higher case-fatality ratio than Africa, due to enhanced diagnostic testing of 
persons from remote areas with fatal disease, rather than an indication of a more virulent strain of 
the disease (Possas et al., 2018). Moreover, YF is challenging for health providers to diagnose 
during early stages of infection because of asymptomatic symptoms or similar symptoms to other 
viral infections in South America like Zika, Dengue or Chikungunya. 
1.3 Yellow Fever Prevention 
Vector control is a crucial method to prevent the spread of the YF virus. Endemic 
populations should be properly trained on how to use insecticides or repellents, remove stagnant 
or infested water sources, and how to dispose garbage properly in order to help reduce YF 
transmission and other vector-borne illnesses. In addition, people living in high-risk areas should 
be aware of mosquito activity, especially during dawn and dusk periods of the day. Other 
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behavioral initiatives include promoting physical barriers, like wearing light-colored clothes and 
long sleeves, or using bed netting, and household screens. Lastly, as a clinical prevention method, 
infected patients should be temporarily isolated indoors away from potential mosquito activity to 
reduce the possibility of spreading the virus to uninfected mosquitos with their lingering viremia 
(Tauil, 2010). 
1.4 Yellow Fever Vaccination 
With only supportive treatment, the most effective prevention method to reduce morbidity 
and mortality is through vaccination.  In 1937, Max Theiler developed the 17D live attenuated YF 
vaccine and is now prepared by culturing the 17D-204 strain of the YF virus in living avian leukois 
virus-free chicken embryos (Cupertino et al., 2019). The vaccine contains sorbitol and gelatin as a 
stabilizer and is hermetically sealed under nitrogen.  Its lyophilized makeup extends the shelf life 
and makes the vaccine more convenient for transport. Each vial of the vaccine is supplied with a 
separate vial of preservative free sterile diluent, which contains Sodium Chloride Injection USP.  
The YF vaccine is formulated to contain no less than 4.74 log10 plaque forming units (PFU) per 
0.5 mL dose throughout the life of the product (World Health Organization, 2016). 
To prevent further YF outbreaks, the WHO “End Yellow fever Epidemics” has advised 
Brazil to carry out catch-up vaccination campaigns to boost levels of immunity up to 80% among 
unprotected pockets of the population (World Health Organization, 2016). Both routine childhood 
immunization programs and mass vaccination campaigns are strategies to increase greater 
immunity.  The YF vaccine is safe, affordable, and only requires a single dose. Vaccine recipients 
develop protective levels of neutralizing antibodies within 10 days and protective lifelong 
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immunity within 30 days of vaccination (Staples, Gershman, Fischer, & Centers for Disease 
Control and Prevention, 2010). The vaccine is delivered subcutaneously to anyone 9 months of 
age and older, living in or traveling through high-risk areas.  Contraindications for the YF vaccine 
include anyone less than 6 months old, immunocompromised, person with an egg allergy, and 
elderly persons over 60 years old. In addition, anyone who is pregnant, breastfeeding, or living 
with HIV should speak with their healthcare provider to discuss the risk of disease and potential 
adverse vaccine effects. 
1.4.1  Yellow Fever Supply Chain 
During immunization supply chain, YF vaccine must undergo proper storage and handling 
methods to stay in favorable conditions through all links of transit. Its lyophilized makeup requires 
it to be stored at 2° to 8°C (35° to 46°F) and can be safely stored for up to two years or more at - 
20° to 4°C (World Health Organization, 2016). In addition, this vaccine requires reconstitution by 
the provider who must restore it back to its original state with the addition of a diluent. 
Reconstituted vaccines are unstable, so it is important to keep them in ice baths and to never freeze 
before administering them. After the end of every six-hour immunization session, it is important 
to discard all opened vaccines and diluents to reduce the risk of contamination. Healthcare 
providers must persevere the potency for all unopened vaccines by storing and transporting them 
back to their stable temperature of 2° to 8°C. 
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1.5 Immunization Supply Chain 
Immunization supply chain, also known as vaccine cold chain, is one of public health’s 
most successful strategies for vaccine coverage in both urban and remote settings throughout the 
world. Vaccine supply chain was created separately from other medical distribution systems to 
assure timely access and control of vaccines (Lloyd & Cheyne, 2017). This systematic method is 
designed for products that are not naturally heat stable to remain their specified temperatures. As 
a temperature-control system, vaccines must be thermally maintained through every link of transit 
starting with the manufacturing plant, transport, delivery, facility, and lastly when administered by 
the provider.   
Protocols for immunization supply chain incorporate vaccine inventory management, 
storage and handling equipment, transport, delivery, preparation, and injection. These protocols 
are set into place through operating procedures conducted by staff members. Vaccine inventory 
management oversees the flow of vaccines, orders, and stock rotation.  Storage and handling 
guidelines include specific labeling and storing procedures.  Vaccine storage equipment includes 
electrical outlets, warning signs, and safety locks.  These functions must keep the product cold 
with temperature monitoring devices.  Vaccine delivery is the process of unpacking, recording, 
and thoroughly checking deliveries. Vaccine transport is dependent on final location.  Transport 
equipment includes portable cold storage units used for long-distance transport, like day clinics in 
the field or during emergencies. The final step before vaccination is vaccine preparation. 
Healthcare providers must create a specific location to prepare and draw up vaccines to avoid cross 
contamination.  It is important to only draw up and prepare a vaccine at the time of administration. 
Providers should follow a safety guard rule when administering a vaccine. For instance, the seven 
rights rule ensures effective vaccination by identifying the right patient, vaccine, time, dose, route, 
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site, and documentation.  Guidelines with immunization supply chain are imperative to public 
health as they continually assist with the prevention and eradication of vaccine-preventable 
diseases. 
Unfortunately, each year storage and handling errors are the results of poorly trained staff 
or failures in the critical areas of vaccine inventory, unreliable storage or temperature monitoring 
equipment.  As a result, these supply chain failures can create long term consequences like 
financial loss for manufactures, public and private partners, and the community. Potency reduction 
and/or inadequate immune response can result from cold chain failure and lead to additional 
consequences of revaccination for patients.  This requires additional time and resources for patients 
and their providers. If patients refuse revaccination, this could further decrease coverage and 
heighten the risk of contracting a serious vaccine-preventable disease.  Lastly, supply chain failure 
can damage the public confidence of vaccines towards the government and healthcare providers 
for routine immunizations or future vaccine campaigns. 
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2.0 Methods 
A PubMed (NLM) search query on YF and Brazil was created prior to assistance, see Table 
2 for detailed summary.  Medline (Ovid) and SciELO (ScieELO Network) searches were with the 
assistance of a public health librarian. The date of the last search was October 16, 2019. Concepts 
that made up the searches were: Yellow fever, vaccination, Brazil/South America, mosquitoes, 
urban/rural, and supply chains. A combination of MeSH terms and title, abstract, and keywords 
were used to develop the initial Medline search which was checked against a known set of studies. 
The search in SciELO focused on Brazil and Yellow fever. Strategies and dates searched for each 
database can be found in Table 2. All articles were thoroughly screened for availability of full 
English text. Zotero (Corporation for Digital Scholarship) was used to store all citations found in 
the search process. 
2.1 Inclusion Criteria 
To be included in this review, articles focused on the ongoing challenges contributing to 
the recent YF outbreaks in Brazil from 2016 to today. The search was limited to full abstract and 
complete English text. No specific date range was conducted, instead I manually filtered through 
articles addressing the recent YF epidemic from 2016 to today.  Studies examining deforestation, 
government policy, YF coverage immunity and other vaccine supply chain challenges regarding 
the recent YF outbreaks in Brazil were the targets in this search. See Table 2 for summaries of all 
database searches and Table 1 for detail search strategy. 
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Figure 1. Condensed flowchart of literature included and excluded 
2.2 Exclusion Criteria 
Results were limited to causal factors contributing to the 2016 to 2019 YF outbreaks in 
Brazil; studies outside criteria were eliminated. Duplicated articles were removed during the 
10 
screening process. Eligibility was based on title and abstract and studies not addressing the recent 
contributing effects of YF transmission or incomplete English text were eliminated. 
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3.0 Results 
The methods, key findings and limitations from the 29 cited articles are outlined below in 
Table 1.  The results section is arranged into: factors contributing to recent outbreaks in Brazil, 
challenges in YF prevention and control in Brazil, and strategies to address challenges of YF 
control in Brazil; the key findings of each article are categorized and expanded upon in sections 
3.1 - 3.4 of this review. 
 
Table 1. Characteristics of included publications 
Author Methods Key Findings Limitations 
Ashok, A., et. 
al. 2017 
Review • Encourage upgrade of cold chain 
capacity gaps based on current and future 
needs 
• Current cold chain systems are struggling 
to support national immunization 
programs in Brazil 
• Solutions should not be 
adopted in isolation, but as 
part of a broader 
transformation of cold chain 
performance management  
Cândido, E. 
L., et. al. 
2019  
Field 
experiment 
• First documentation of Ae. fluviatilis in 
Saboerio, Brazil  
• Experimentally able to transmit YF 
• Uncertainty of urban YF 
transmission to NHPs and 
humans  
Chen, L.H., 
et. al. 2019 
Review • Reemergence of YF outbreaks led to 
vaccine shortages 
• Lack of solutions or 
alternatives provided to assist 
global stockpile if YF 
outbreaks are not contained  
Chippaux, J., 
et. al. 2018 
Review • High deforestation increasing contact 
among human populations 
• Zika and dengue transmission diverting 
public health attention 
• Increase vector control and immunize 
high-risk populations for YF containment 
• Lack of clinical diagnosis of 
YF index cases 
• Unknown flaws for YF 
transmission in Asia  
Cupertino, M. 
do C., et. al. 
2019 
Review • Spatial expansion of YF throughout 
previously considered nonendemic 
regions  
 
• Insufficient diagnostic tests to 
detect YF earlier  
de Paiva, C. 
A., et. al. 
2019 
Multicriteria 
analysis  
• Proximity to Atlantic Forest domain 
increase vulnerability to YF among 
dense populations  
• Sylvatic YF pattern may not 
represent actual distribution 
due to ability to fly long 
distances  
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Ghedamu, 
T.B., et. al. 
2019 
Analysis of 
policy 
surveillance 
research on 
national 
immunization 
law  
• Law and policies assist as tool to protect 
communities and prolong public health 
• Success of vaccination programs is only 
attainable with high rates of 
immunization coverage  
• Gaps in national immunization laws 
• Mandatory vaccinations 
remain controversial  
• Unable to restrict human 
rights  
Haidari, L.A., 
et. al. 2017 
Simulation 
modeling 
study 
• Solar refrigerators provide savings over 
electrical refrigerators for supply chain 
strategies 
• WHO and GAVI guidelines 
may not capture all solar 
situations 
• This model is a simplified 
representation of reality thus 
cannot capture every feature  
Jácome, R., 
et. al. 2019 
Review  • Climate change from human activities 
initiate rapid spread of arboviruses  
• Concern for RNA viruses due to high 
mutation rates, absence of proofreading 
mechanisms, and ability to cross over 
species  
 
• Asymptomatic or mild cases 
are underreported thus 
underreporting the actual 
burden of YF  
Klitting, R., 
et. al. 2018 
Review 
 
• Transmission dynamics of YF virus 
• Possible spread of YF to Asia 
• Need for more NHPs 
surveillance techniques  
• Limited data on genetic 
resistance to YF among Asian 
populations 
Kristensen, 
D.D., et. al. 
2016 
Qualitative 
research study 
through semi-
structured 
interviews 
• Brazil’s primary vaccine improvement 
demand was for better heat stability 
technology 
• Brazil’s lack of GAVI-
eligibility  
• Surveyed small number of 
individuals, not representative 
sample 
• Biased opinions of 
stakeholders  
Lloyd, J., et. 
al. 2017 
Review • Need to create reliable cold chain 
systems  
• Advance technologies shall reduce costs 
and management measures  
• Continuous challenges to 
reach remote populations  
Massad, E., 
et. al. 2003 
Mathematical 
analysis of R0 
• Great number of non-vaccinated people 
living in Ae. aegypti infested areas in 
São Paulo  
• Assume Ae. Aegypti causes 
both Dengue and YF when 
estimating R0 
Moeti, M., et. 
al. 2017 
Editorial 
review 
• Still places in the world where vaccines 
are not being delivered  
• Strategies to overcome supply 
chain costs for low-income 
countries  
Monath, T.P., 
et.al. 2002 
Review • YF stockpile shortage due to recent 
global outbreaks  
• Recommend fractional dosing to create 
greater immunity coverage 
• Need for stronger YF surveillance and 
vector control  
• Lack of information regarding 
potential YF spread to Asia  
• Limited data on fractional 
dose immunity duration 
• Limited clinical testing on 
children with fractional doses 
Table 1 Continued 
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Moussallem, 
T. M., et. al. 
2019 
Retrospective 
analysis on 
secondary 
data 
• Highest intermediate incidence rates 
among forested areas during wet season 
in Espírito Santo, considered YF free 
until 2017 
• Males more affected due to deforestation 
occupation 
• Secondary data regarding 
limited epizootic details 
preceding human epidemic 
Nava, A., et. 
al. 2017  
Review • Environmental changes impact the 
emergence and reemergence of infectious 
vector-borne diseases  
• Lack of holistic approaches 
available to mitigate control of 
YF  
Pagliusi, S., 
et. al. 2018 
Review • Improve supply chain tools and delivery 
methods of existing vaccines  
• Importance for partnerships developing 
countries in fostering innovations for 
public health 
• Lack of innovative solutions 
to address declining 
vaccination coverage  
Possas, C., et. 
al. 2018 
Review • Human behavior and ecological changes 
promote YF incidence in Brazil  
• YF fractional dosing is not 
compliant with IHR  
• Ineffective NHPs 
immunization models and 
strategies  
Romano, A. 
P., et. al. 2014 
Retrospective 
analysis on 
secondary 
data 
• Recent outbreaks resulted in revised 
vaccination guidelines in Brazil 
• Mass vaccination leads to increased 
detection of adverse effects  
• Scare data on YF emergence 
in non-endemic areas  
Saraiva, J. F., 
et. al. 2019  
Field 
experiment  
• First record of Ae. albopictus in Amapa, 
Brazil  
• Ability to transmit YF through laboratory 
tests  
• Not considered a natural 
vector of YF  
Shearer, F. 
M., et. al. 
2017 
Retrospective 
analysis on 
secondary 
data 
• Increase in general vaccination coverage, 
but notable gaps in YF vaccine in Brazil  
• Brazil not meeting WHO immunization 
coverage recommendations  
• Incomplete high-resolution 
data lacks certainty of 
vaccination coverage 
estimates  
Silva, S.F., et. 
al. 2018 
Prospective 
cohort 
• Incomplete immunizations were higher 
with YF vaccine in Brazil  
• Immunization strategies should consider 
the vulnerability of older preschool age 
children and lower socioeconomic 
classes  
• Lack of data from dates when 
vaccine doses were 
administered  
• Limited age group of 13 to 35 
months  
• Only two cities represented in 
Brazil  
Table 1 Continued 
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Staples, J. E., 
et. al. 2010 
Review • Revise recommendations for YF vaccine 
• At risk populations include unvaccinated 
foreign travelers visiting endemic regions 
and unvaccinated people living in 
endemic regions  
• Increase vector control and personal 
protective measures  
• Simultaneous vaccination with YF and 
inactivated vaccines is safe  
• Need for more suspected risk 
factors for serious adverse 
effects  
• Lack of population and NHPs 
data on YF due to nature of 
YF transmission in rural 
settings  
• No drug treatments or clinical 
trials conducted  
• Limited data on regarding 
safety and immunogenicity of 
YF vaccine in pregnancy  
• Limited data on adverse 
effects or safety with 
breastfeeding  
• Limited data on suspected risk 
factors for serve adverse 
effects of YF vaccine 
Tauil, P. L., 
2010 
Review • Expand vaccination to reduce wild type 
YF in Brazil 
• Improve surveillance to enhance early 
detection of outbreaks  
• Insufficient ecological and 
epidemiological assessment in 
forested areas  
Veras, M. A. 
S. M., et. al. 
2010 
 
 
 
Survey on YF 
vaccine 
coverage 
• Improvement on YF routine infant 
immunization is needed in endemic and 
non-endemic regions due to potential 
spread 
• Survey only conducted in 
capital cities, not represented 
in rural areas  
• Non-endemic regions were not 
accounted for  
 
WHO | 
Yellow fever 
– Brazil, 2019 
 
Whitepaper  • Over 80% of recent cases are men 
• Highest outbreaks occurred with their 
last two seasonal periods 
• Brazil increased its immunization 
policies in more municipalities 
• WHO recommendations may 
not be fulfilled by Brazil 
• Project further transmission in 
upcoming seasonal pattern  
World Health 
Organization, 
2016 
Review • Outbreaks are increasing the demand for 
YF vaccine  
• Fractional dose of YF provides dose-
sparing option for recent outbreaks 
• Fractional dosing is not a long-term 
strategy nor be replaced with established 
routine immunization practices  
• IHR lack of proof for YF 
entrance among travelers  
• Small non-representative 
sample sizes in fractional dose 
studies and narrow age range  
• Only short-term follow up 
with fractionally dosed 
subjects  
World Health 
Organization, 
2018 
Whitepaper • WHO advocates for YF vaccination 
requirement for foreign travelers entering 
at-risk countries for YF 
• Brazil is a country at risk for YF 
transmission 
•  Country requirement are 
subject to change at any time 
• Last update 11/05/2018  
 
Table 1 Continued 
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3.1 Yellow Fever in Brazil 
YF has a long history in Brazil, it was first recorded after the Pernambuco epidemic in 
Recife and Olinda in 1685 (Chippaux & Chippaux, 2018). Historians believe the YF virus was 
transmitted by a boat carrying slaves from Cape Verde Islands that had stopped in Guadeloupe, 
where YF was endemic if not epidemic, before reaching the Brazilian coast. The prevalence of YF 
was greatly reduced, until the next outbreak occurring in 1849, which was attributed to importation 
of the slave trade from Africa (Chippaux & Chippaux, 2018). Since the invention of the YF 
vaccine, Brazil’s efforts to control YF have included mass vaccine campaigns, which drastically 
reduced YF incidence rates through the 1930s. Since 1942, there has been no record of YF virus 
being transmitted by the domestic cycle in urban settings (Moussallem et al., 2019). This is 
primarily due to the combination of vector control efforts and higher levels of vaccination coverage 
in urban areas. In addition, low migration rates between urban centers and enzootic reservoirs are 
limited, but vaccination programs encourage those who travel to enzootic areas to be vaccinated 
at least 10 days before traveling.   
Brazil’s current YF epidemic is now drifting from its original epicenter to more populated 
southeastern states, see Figure 2. Due to the southeastern states landscape, YF transmission is 
crossing over the forested areas into nearby cities. When the YF virus reaches the edge of the 
forests it significantly increases contact between humans and the Haemogous or Sabethes 
mosquitoes. With little to no protection from infected mosquitoes, sylvatic YF transmission occurs 
mostly in unvaccinated young men on jobsites in forested areas in Brazil (Staples, Gershman, 
Fischer, & Centers for Disease Control and Prevention, 2010). In Brazil, where deforestation is in 
demand, occupations involving lumbering and forest clearing for building or road construction 
have been linked to human infection. Conversely, YF cases from Ae. Aegypti transmission have a 
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higher prevalence infecting women and children due to greater breeding grounds near homes in 
urban areas; this is more prevalent in Africa. Overall, YF transmission varies based on graphic 
location with different mosquitoes targeting different populations among age and sex. 
 
 
Figure 2. Ongoing Yellow fever viral spread from 1999 
(Possas et al., 2018) 
 
The majority of sylvatic YF transmission occurs within the Amazon region along with 
other outbreaks occurring around its border.  Figure 2 highlights the vast geographic expansion of 
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the YF virus throughout Brazil from 1999 to today. The pattern illustrates YF transmission 
migrating through various Brazilian biomes, thus causing the recent outbreaks into the Southeast 
and Atlantic Forest. The black dashed lines show YF viral spread from 1980’ until 2010.  The 
white lines show YF viral spread from 2016 to the current outbreaks in the Southeast regions of 
Brazil. Over the last decade, there have been numerous developmental factors contributing to YF 
transmission including climate, human behavior and economy changes. The reemergence of YF 
throughout Brazil is creating additional YF prevention and control methods, along with revisions 
for vaccination (Romano et al., 2014). These unwanted changes have assisted ideal vector 
transmission conditions for ongoing expansion of YF cases and case fatalities (Possas et al., 2018). 
In addition, what was previously considered risk-free and under-vaccinated zones are now 
contributing to the distribution of confirmed cases, due to the YF expansion.  
Recent outbreaks of YF in Brazil have taken place largely in metropolitan regions around 
the country, putting 35.8 million people at risk for infection (Klitting, Gould, Paupy, & de 
Lamballerie, 2018). In May 2017, 130 cities were affected with 792 positive human cases and 274 
confirmed fatalities (CFR – 35%) among eight Brazilian states to include most populated Rio de 
Janeiro, São Paulo, and the Distrito Federal (Jácome et al., 2019).  These regions are susceptible 
to transmission because of their densities and proximity to the Atlantic forest region.  The drastic 
incidence prompted Brazilian authorities to expand mass vaccination coverage with the use of 
fractional dosing and door-to-door visits. More than 26 million emergency vaccine doses were 
administered in 2017. Moreover, between July 2017 and May 2018 there were 1,266 cases with 
415 deaths CFR 32.8% (Jácome et al., 2019). By the end of March 2018, this outreach covered 
78.6% of the targeted population, equivalent to 17.8 million people (Jácome et al., 2019). 
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Fortunately, with surveillance initiatives from July 2018 to March 2019, there has been a reduction 
in YF human and NHPs cases compared to the last three years.  
 
 
Figure 3. Distribution of confirmed human Yellow fever cases in Brazil, 2016 - 2019 
 (“WHO | Yellow fever – Brazil”). 
 
Further detail of the recent YF transmission is shown in Figure 3. This graph highlights a 
wave pattern of the seasonal transmission among YF with greatest incidence rates between the 
months of December and May. The first epidemic curve in the 2016-2017 season confirmed 778 
human cases to include 262 deaths. The second epidemic curve in the 2017-2018 season confirmed 
1,376 human cases to include 483 deaths (“WHO | Yellow fever – Brazil”). The smallest epidemic 
curve, from July 2018 to March 2019, accounts for 75 confirmed human cases with 17 deaths.  
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Figure 4. Distribution of both human and NHPs cases in Southeast region, 2018 - 2019 
(“WHO | Yellow fever – Brazil”.). 
 
Given the geographical expansion of YF cases in both human and non-human primate 
cases, the number of areas with recommended vaccination has increased from 3,526 municipalities 
in 2010 to 4,469 municipalities in 2018 (“WHO | Yellow fever – Brazil”). This public health 
response initiated the process of vaccinating unvaccinated residents within at-risk regions. Of the 
2018–2019 cases, Figure 4 highlights YF incidence in the states of São Paulo (62), Paraná (12), 
and Santa Catarina (1). Significant findings report 88% (66/75) are males, median age is 43 years 
old, and 71% (53/75) are rural workers (“WHO | Yellow fever – Brazil”). This data further supports 
who is most at-risk due to the progression of deforestation and lack of vaccination policies. 
Moreover, these densely populated regions reside partially or fully within the Atlantic forest 
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domain, which further contributes to the high prevalence of sylvatic YF cases in the states of Minas 
Gerias, Espírito Santo, Rio de Janiero, San Paulo, and Parana. 
Another factor contributing to the recent YF outbreaks is the spread of uncontrolled 
epizootic cases. Epizootic is defined as a sudden die-off of NHPs in a small geographic area.  
Sightings of ill monkeys or carcasses are reported to local health departments, which conduct 
investigation and collect specimens for laboratory testing (Romano et al., 2014). NHPs are 
extremely susceptible to the virus and its infectious spread among the primate population cannot 
be stopped. Despite the reduction in the number of human YF cases after May 2017, there was a 
greater increase in the number of epizootics in Brazil. Reports show between July 2018 and May 
2018, over 7,000 probable YF infections in NHPs were reported, with 752 confirmed in lab 
(Jácome et al., 2019). As a result, these outbreaks are putting endemic populations at greater risk, 
which is increasing the demand for the YF vaccine. Moreover, with the recommendation of 
vaccination and use of fractional doses it is exhausting both the national and global stockpiles; 
thus, it is imperative for their government to look for other sustainable solutions.  
3.1.1  Brazilian Ministry of Health Response  
In Brazil, YF is a notifiable disease due to its effects on morbidity and mortality among 
those infected.  The Brazilian Ministry of Health’s national surveillance system reviews reports of 
suspected YF cases and epizootic events from state and municipal health departments.  Their 
mission is to reduce the number of sylvatic cases and continue zero YF incidence in urban areas 
(Tauil, 2010). Specified before, there have been no confirmed cases of YF in urban areas since 
1942.  This achievement is due to the multiple control programs to include an in-depth surveillance 
program of Ae. Aegypti and immunization campaigns that create a blocking belt of vaccinated 
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individuals living in the transition zone between urbanized areas and enzootic regions (Massad, 
Burattini, Coutinho, & Lopez, 2003). 
Due to the nature of YF, the epidemiology is difficult to capture because it relies on passive 
surveillance from both humans and NHPs (Klitting, Gould, Paupy, & de Lamballerie, 2018). 
Remains of NHPs serve as a surveillance tool and act as a warning signal for potential outbreaks 
or epidemics.  Their remains allow researchers to account for incidence cases and additional 
specimen data.  In addition, surveying mosquitos is as another tool used by researchers.  Current 
practices on mosquito baiting and other capturing methods can identify specific species and test 
for positive YF infectivity. Other surveillance initiatives include raising YF awareness among 
healthcare workers, mandating notification of persons with hemorrhagic syndromes, and 
investigating unknown causes of human deaths (Romano et al., 2014). Increasing all forms of 
surveillance allows researchers and policy makers to access the magnitude of YF, evaluate control 
measures, and facilitate further planning.  
3.2 Yellow Fever Vaccine in Brazil  
The YF vaccine has been used in Brazil since the invention in 1937 through mass 
immunization campaigns.  Mass immunization campaigns target at risk areas where there is a low 
vaccination coverage.  Community outreach and education on vaccination campaigns can reach 
larger populations in short periods of time to prevent further exposure. Through the National 
Immunization Program access to vaccines are free in Brazil (Silva, Barbosa, Batalha, Riberio, & 
Simoes). As a part of the Brazilian national immunization program, Bio-Manguinhos Laboratory 
provides YF vaccines to public vaccination clinics (Tauil, 2010). In 1991, Brazil enacted routine 
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vaccination schedules for infants in endemic regions to help reduce disease prevalence (Veras, 
Flannery, de Moraes, da Silva Teixeira, & Luna, 2010). Moreover, the YF vaccine is routinely 
administered at the same time as the measles-mumps-rubella (MMR) vaccine.  This joint 
vaccination process assists with immunization convenience for health providers and families, 
while improving greater coverage among multiple infectious diseases. 
Up until March 2017, the Brazilian Ministry of Health implemented the double-dose 
vaccine regimen for YF.  This second dose was administered after 10 years of the initial vaccine 
to produce long-term immunity (Cupertino et al., 2019).  Despite WHO guidelines declaring a 
single dose was enough to confirm full immunity, Brazil was the only country continuing the 
double-dose vaccine. However, due to the recent outbreaks and epidemiological situation in the 
country over the last three years, the Brazilian Ministry of Health adopted the WHO 
recommendations and started to recommend only one dose of the vaccine as of April 5th, 2017 
(WHO | Yellow fever vaccination booster not needed). Individuals who had been vaccinated at 
any time in their life no longer need the second booster dose and are considered fully immunized. 
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Figure 5. South America vaccination coverage, 1970 - 2016 
 (Shearer et al., 2017)  
 
Figure 5 portrays YF vaccination coverage from 1970 to 2016 in South America. 
Throughout each decade, Brazil (circled in red) has consistently increased YF vaccination rates. 
During the 1970s, the enactment of routine immunization programs for children and young adults 
have contributed to YF vaccination coverage. YF vaccination is primarily delivered through three 
different vaccination models; routine childhood vaccination targets infants aged around 9 months 
in at-risk regions, mass vaccination campaigns are conducted with an outbreak response; and 
vaccination of people travelling to high-risk areas (Shearer et al., 2017). Unfortunately, from the 
1990s until today, there have been numerous sylvatic YF outbreaks prompting further mass 
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vaccination coverage campaigns. As a result, the 2016 vaccination coverage rates were estimated 
to be much greater for most parts of the country.  
Furthermore, effective measures greatly reduce the risk of YF transmission. Enforcement 
of effective vector control, vaccination, and disease surveillance can all prevent further outbreaks. 
The results of the Shearer study highlight the progression of closing the immunization gap in high-
risk regions, while identifying populations most susceptible to yellow fever infection (2017). 
Unfortunately, YF cannot be universally eradicated due to the presence of NHPs reservoirs, which 
maintain the ongoing sylvatic transmission cycle of the virus in remote forested or rural settings. 
According to the International Health Regulations from WHO, YF is the only infectious disease 
specified for which countries may require proof of vaccination from travelers as a condition of 
entry into their country (2016). The purpose of the IHR is to “prevent, protect against, control and 
provide health response to the international spread of disease in ways that are commensurate with 
and restricted to public health risk, and which avoid unnecessary interference with international 
traffic and trade” (“WHO | What are the International Health Regulations and Emergency 
Committees?”). The legality of the IHR is important as it protects international travel and transport 
when crossing borders. As of July 2016, the WHO announced Brazil to be considered at-risk for 
YF transmission. However, Brazil does not require YF vaccination for travelers arriving from 
neighboring or foreign countries. Similarly, Peru and Columbia are also at-risk countries for YF 
and do not require proof of YF vaccination.  Whereas, other neighboring countries at-risk for YF 
include Bolivia, Suriname, French Guiana, Guyana, and Paraguay all require proof of vaccination 
for at least 9 months to 1 year of age (World Health Organization, 2018). Lack of vaccination 
security from foreign travelers or workers in Brazil create greater risk for further YF transmission. 
Moreover, the feasibility of implementing this measure at border crossings remain an additional 
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challenge and may not be logistically feasible if legalized given the porous borders at crossings 
points (World Health Organization, 2016). Ultimately, to see greater vaccination improvements it 
is up to Brazilian policy makers and other government officials to extend proof of YF vaccination 
among travelers entering Brazil. 
3.2.1  Fractional Dose of Yellow Fever 
To add to the recent YF outbreaks in Angola, Brazil and the Democratic Republic of the 
Congo, the vaccine global stockpile is diminishing as the demand for the YF vaccine is increasing, 
thus putting greater risk for unimmunized populations in endemic areas (World Health 
Organization, 2016). The global stockpile is replenished every year to sustain ample supplies to 
rapidly respond when needed, but without proper vaccine inventory or funding for vaccination 
campaigns, countries not only face the effects of morbidity and mortality, but also social and 
economic disruption. Future stockpile concerns include densely populated areas like cities which 
could overwhelm the emergency response system and ultimately jeopardize global health security 
(Klitting, Gould, Paupy, & de Lamballerie, 2018). As a result, the Brazilian Ministry of Health 
initiated other vaccination alternatives to overturn the strained stockpile.  
In January 2018, the Brazilian Ministry of Health, with the approval of the WHO, 
announced that it would initiate fractional dosing as an alternative to achieve maximum coverage.  
During a public health emergency, this immunization strategy is used to control an infectious 
outbreak when current vaccine supplies are limited, while assisting the increase of the current local 
or global stockpile (Pagliusi, Dennehy, Kim, & DCVMN AGM Organizing Committee, 2018). 
The fractional dose campaign occurred in 76 municipalities in the states of São Paulo, Rio de 
Janerio, and Bahia to expand vaccination coverage and prevent further outbreak. The Ministry of 
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Health focused on these municipalities because of the recent sylvatic YF cases nearby and their 
high population densities of unvaccinated residents. As one of the few countries that manufactures 
the YF vaccine, Brazil enlisted Bio-Manginhos to implement the fractional dose vaccines in efforts 
to vaccinate the entire population of 77 million people by April 2019 (Chen, Kozarsky, & Visser, 
2019). The fractional dose applied was 0.1 mL, 20% of the standard 0.5mL amount, which allows 
five people to become partially vaccinated with the use of one standard vial (Cupertino et al., 
2019). Contrarily, fractional doses of YF are not yet fully compliant with IHR and therefore should 
only be used in outbreak settings until more data is gathered. 
Experts suggest that the most expedient approach to increase YF vaccine supply during a 
large outbreak or emergency would be to use a lower dose of the YF vaccine to immunize those at 
risk. Stretching the supply of the YF vaccine through fractional dosing can protect more people 
during a YF outbreak. From the Roukens study, researchers show that 1/5th of the regular dose of 
YF can provide the same immunogenicity as the full dose against the disease for at least 12 months 
(World Health Organization, 2016).  Another study by Martins, showed 1/46th dilution of the full 
dose resulted in equivalent humoral response as full dose (World Health Organization, 2016). At 
30 days these participants showed seroconversion in 97%.  All fractional doses of YF vaccine must 
have a minimum dose administered, preferentially 3000 IU/dose, but no less than 1000 IU/dose 
and the minimum volume of administration should be not less than 0.1 ml (World Health 
Organization, 2016). To reiterate, fractional dosing is not a long-term solution, public health 
departments cannot replace it with established routine immunization practices and must 
revaccinate people with the full dose once available.  
With fractional dosing only being used in emergent situation, many limitations can apply.  
Although studies have shown immediate immunity response, it only provides short-term 
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immunity.  Thus, it is imperative to let recipients know a fractional dose of YF will not cover 
lifelong immunity and recipients should return to their healthcare providers to get fully vaccinated 
once the situation normalizes. Another limitation includes these study populations who 
participated in fractional dose research are likely different from the effected populations living in 
YF endemic areas.  People living in YF endemic regions may have a different biological makeup 
among the relationship with flavivirus exposure and genetic background (World Health 
Organization, 2016).  In addition to study populations, the data only represented adults, which 
limits the entirety of an actual population. Therefore, more research needs to be conducted to 
further examine YF fractional dosing as a public health tool.  
3.2.2  Adverse Effects of Vaccine 
Adverse effects from the YF vaccine is one of the leading challenges related to successfully 
vaccinating the entire country. The YF vaccine has been used for decades and side effects are 
generally mild, but there are continuous cases of adverse events. There have been reports of rare 
life-threatening allergic reactions, alters to the nervous system and/or internal organs (Kaiser, 
2018).  In Brazil, it is estimated that 1 and 21 cases per million doses are fatal (Massad, Burattini, 
Coutinho, & Lopez, 2003). Studies have also shown that vaccination of adults without prior 
immunity may increase rates of severe events, because risk is greatest with first vaccination and 
appears to increase with age (Romano et al., 2014). Therefore, healthcare providers caution 
vaccination in adults who are older than 60 years of age.  
Mass vaccinations have shown an increase in adverse side effects, which may be better 
detected and addressed through improved surveillance.  Studies suggest there is an association 
with lower socioeconomic and demographic factors to incomplete childhood immunizations due 
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to limited access and fear of adverse effects (Silva, Barbosa, Batalha, Ribeiro, & Simões). To 
reduce the stigma against the YF vaccine, public health officials and healthcare providers need to 
educate and discuss all indications for vaccination, including contraindications and precautions for 
persons who might be at increased risk of severe adverse events (Romano et al., 2014). Open 
communication from trusting health professionals may reduce associated stigma of vaccines for 
patients who may have concerns with personal or religious beliefs regarding YF vaccination. 
Likewise, nonclinical adverse effects like human suffering, economic loss due to infeasibility to 
work, treatment costs, and reduction of tourism and exports can lead to additional consequences 
of the morbidity and mortality of YF (de Paiva et al., 2019). 
3.3 Vaccine Supply Chain Challenges 
With today’s technology and sources of mobility, it is a shame that vaccines are still not 
able to reach all people around the world.  This is largely due to the complexity of vaccine supply 
chain systems.  Vaccines can become lost, damaged, or expired before they reach local health 
clinics or points of use, thus hindering efforts to cover greater immunity (Moeti, Nandy, Berkley, 
Davis, & Levine, 2017). An additional challenge to the vaccine supply chain is the ability to reach 
healthcare providers in remote communities who need more supplies.  This requires meticulous 
control of temperature during storage and transport, specialized cooling equipment, and logistical 
expertise to avoid breakdowns in delivery systems of cold chain equipment (Moeti, Nandy, 
Berkley, Davis, & Levine, 2017). Thus, it is imperative to establish a renewed focus on next-
generation supply chains that can safely and reliably manage, store, transport, and deliver vaccines.  
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The point of use is vital to closing the immunization gap for not only YF, but for all vaccine-
preventable diseases.  
Although improving supply chain equipment can expand vaccination coverage, an 
additional challenge is reaching unvaccinated people in remote locations. Remote populations 
include people living off rivers, in mountains, on islands, and as nomadic tribes. Logistically 
reaching out to these communities costs up to five times more than in urban areas to fully immunize 
someone (Lloyd & Cheyne, 2017). Yet the cost-effectiveness of investments is compelling: recent 
research suggests that for every dollar invested in childhood immunization, there is a return on 
investment of US $16 through savings in health care cost, wages, and productivity due to illness 
in low and middle-income countries (Moeti, Nandy, Berkley, Davis, & Levine, 2017). 
Furthermore, cold chain systems are struggling to support national immunization programs due to 
vast coverage demands, inadequate equipment and cold chain capacity (Ashok, Brison, & 
LeTallec, 2017). WHO and Global Alliance for Vaccines and Immunizations (GAVI) both 
recommend solar refrigerators for regions with limited time of electricity (Haidari et al., 2017). 
Solar refrigerators are less costly than on-grid refrigerators and are only used when electric 
supplies are unpredictable and can help overcome these challenges. 
3.4 Deforestation in Brazil  
Deforestation is the process of permanently clear cutting or burning away forests in order 
to make land more available for agriculture, cattle ranching, or harvesting timber. In 2019, the 
State of Amazons in Brazil declared a state of emergency over the wildfires and deforestation 
(Cereceda, 2019). As a result, sylvatic YF transmission has become the leading cause of infection 
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to NHPs and unvaccinated people in these once forested areas. With deforestation, Haemogous or 
Sabethes mosquitoes are no longer enclosed in their forest reservoir and open to migrate outwards. 
What was once a barrier containing sylvatic transmission, is now a vulnerable area where infected 
mosquitoes can infect the edges of vegetation where forests and cities intermix (Moussallem et al., 
2019).  This especially increases sylvatic YF transmission among workers with forest-related 
occupations and people living in nearby villages or cities.  
In 2016, Brazil lost almost 8,000 square kilometers of forest through deforestation, 
according to NGO Observatório do Clima, this was a 29% increase to 2015 (Veiga, 2017). 
Notoriously known as one of the highest deforestation contributors, Brazil does not seem to be 
slowing down. As a result, the WHO has warned neighboring countries with similar ecosystems 
to Brazil of the possible increase of YF transmission and the importance of vaccination to avoid 
sylvatic YF outbreaks. It is important to remember that deforestation is a public health threat, not 
only to the effects of climate change and biodiversity, but also to animal reservoirs and human 
inhabitants. 
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4.0 Discussion 
4.1 Recommendations 
4.1.1  Increase Yellow Fever Vaccination Coverage 
Routine vaccination to all unvaccinated people living in Brazil should be highly 
recommended because of Brazil’s YF history, prevalence of other vector-borne diseases, and the 
ongoing YF outbreaks. This would strengthen adherence to routine vaccinations and avoid 
unnecessary future mass vaccination campaigns. Moreover, this is a more cost-effective plan in 
the sense that it optimizes allocation of limited resources and prevents unwanted healthcare costs 
(Massad, Burattini, Coutinho, & Lopez, 2003). Additionally, reducing the stigma associated with 
the YF vaccine and its adverse effects is fundamental when proposing greater vaccine coverage. 
The Brazilian Ministry of Health and healthcare providers should continue to advocate YF 
vaccination and educate at-risk populations who reject immunization for religious or personal 
belief. 
Equally important, with the increase of NHPs being exposed to more open and public 
surroundings, the Brazilian Ministry of Health should create a policy to reduce potential YF 
circulation with methods to vaccinate NHPs. Vaccinating NHPs in confined parks and forests 
reserves contiguous to urban areas as well as animals maintained in zoos is already underway 
(Possas et al., 2018). Since NHPs live and hide in forested areas, it would be near impossible to 
physically vaccinate all of them with an injection.  More research needs to be conducted to develop 
other strategic delivery strategies to vaccinate NHPs. Examples could include food containing the 
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recombinant YF vaccine, transgenic fruit, or other technological alternatives (Possas et al., 2018). 
It should be noted, vaccinating NHPs protects immunity for both animal and human populations, 
while preserving greater biodiversity. 
Another suggestion to increase YF vaccination is to promote simultaneous vaccinations. 
YF vaccine can be administered simultaneously or 30 days apart from other live viral vaccines to 
limit the impaired effects (Staples, Gershman, Fischer, & Centers for Disease Control and 
Prevention, 2010).  There has been no evidence the YF vaccine interfering with the immune 
response when paired simultaneously with the Bacillus Calmette–Guérin, human papillomavirus, 
meningococcal, pertussis, smallpox, tetanus, typhoid or rabies vaccine. In addition, during infant 
routine vaccinations, the YF vaccine can be administered in conjunction with other vaccines to 
include diphtheria, hepatitis A, hepatitis B, influenza, measles-mumps-rubella (MMR), polio, and 
varicella (Veras, Flannery, de Moraes, da Silva Teixeira, & Luna, 2010). Advantages to 
simultaneous vaccinations reduce appointment time for the provider and patient, cut cost of 
transportation, and vaccinate against multiple diseases in less increments.  Moreover, studies show 
routine immunization services in fixed facilities, along with consistent outreach services carried 
into the field help increase vaccine coverage (Lloyd & Cheyne, 2017).  This allows the public to 
be more familiar with vaccination schedules and longer lasting healthcare resources. 
Furthermore, the need for collective work among all stakeholders is imperative to end the 
YF epidemic in Brazil. A study involving Brazilian stakeholders was captured and analyzed among 
other middle to low-income countries with vaccine challenges. Brazil’s main concerns on how to 
understand and improve vaccine products include decreasing vaccine waste, preventing heat 
damage, and simplifying delivery methods (Kristensen, Bartholomew, Villadiego, & Lorenson, 
2016). By collaborating with YF stakeholders to include manufacturers, researchers, and 
 33 
international organizations like WHO, GAVI and National Immunization Program, there is hope 
to advance this shared goal of increasing YF vaccination coverage in Brazil (Pagliusi, Che, & 
Dong, 2019). 
In contrast to the WHO and other neighboring countries, the Brazilian government does 
not require the YF vaccine for foreign travelers or workers coming into country. Recommending 
documentation of the YF vaccine will reduce infectivity and stop the ongoing cycle of outbreaks 
among unvaccinated people. In addition, the Brazilian Ministry of Health needs to further 
emphasize that newly vaccinated people traveling to endemic regions must be vaccinated at least 
10 days prior to travel. This proposed mandatory requirement ties into the idea by Ghedamu and 
Meier, which is to create a national public health law to prevent further infectious disease 
outbreaks. Creating vaccine travel restrictions helps sustain global health security. Furthermore, 
national public health laws could provide requirement around licensure and legal obligation to 
those who want to travel to foreign countries (Ghedamu & Meier, 2019). Not only would this be 
used as a public health tool, but it would allow researchers to better understand the impacts of 
regulated public health outcomes and/or propose new law reforms. 
4.1.2  Increase Yellow Fever Surveillance 
Currently, the primary surveillance systems for YF are passive models that look at previous 
YF diagnoses and remains of infected NHPs. Unfortunately, this data contributes to underreporting 
and incompleteness.  Although resource intensive, active surveillance is recommended due to the 
nature of YF disease and high-risk populations in endemic regions of Brazil.  Ensuring more 
complete YF reports allows researchers and public health officials to monitor trends, patterns, and 
risk factors. This allows further detection of sudden changes in the disease transmission, 
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progression, and distribution. With the collection of data, public health officials and 
epidemiologists can provide information to assist government programs, policies, and priorities. 
This further allows better evaluation on public health programs regarding prevention and control 
measures.  
Apart from this, vector surveillance is imperative due to the rise of other vector-borne 
diseases and pathways.  Recent findings of two potential vector-borne mosquitoes for YF are being 
researched. Aedes fluviatilis and Aedes albopictus are both arboviruses prevalent in Brazil and can 
share the same breeding grounds with Ae. Aegypti. Within experimental models, Ae, fluviatilis has 
demonstrated positive transmission of YF (Cândido, Silva, & Cavalcanti, 2019). Both mosquito 
species are well adapted in rural and urban environments.  Although they are not yet classified as 
natural vectors for YF, this raises a public health concern that they could potentially act as an 
infestation bridge between rural and urban environments (Saraiva et al., 2019). Overall, the 
Brazilian Ministry of Health and other agencies must continue all types of surveillance methods 
to reduce the spread of YF across their county.  
4.1.3  Increase Vector Control Measures 
Another recommendation necessary to reduce further YF exposure in rural and urban 
settings is to continue vector control measures at all levels of government.  For example, local 
prevention methods could include community practices of eliminating potential breeding grounds 
like removing stagnant water and using netting or screens as a physical barrier.  State prevention 
methods include regular garbage pickup and spraying insecticides or repellents to prevent potential 
breeding grounds.  Lastly, as a national prevention measure, immunization is the primary method 
to reduce YF morbidity and mortality. Ongoing research is underway to develop innovative vector 
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control strategies.  A promising study is the use of transgenic male mosquitoes carrying a dominant 
lethal copy gene, causing their offspring to die at the pupation stage (Jácome et al., 2019). Most 
importantly, all control measures must be accompanied with current vector-borne education, so 
the general public is aware of how to safely protect themselves and their families. 
4.1.4  Restrict Deforestation 
The recent outbreaks of YF were most likely driven by human enforced deforestation and 
forest fragmentation for extended transportation and agriculture use, that led to isolated and 
stressed reservoirs of NHPs while indirectly altering the vector expansion. Protection laws against 
industries in urbanization and agriculture are recommended to prohibit or reduce deforestation to 
further prevent vector-borne outbreaks and climate change. Despite, the Brazilian government 
signing the United Nations Framework Convention on Climate Change in 2016, their concerns 
when it comes to deforestation is superficial and can be connected to adverse political and 
economic interests (Nava, Shimabukuro, Chmura, & Luz, 2017).  
Furthermore, there is an interconnecting relationship among deforestation, climate change, 
and infectious diseases. Climate change initiates increased temperature and higher rainfall, thus 
creating more breeding grounds for mosquito vectors.  These effects may affect the survival, 
reproduction, and distribution of disease and their hosts (Nava, Shimabukuro, Chmura, & Luz, 
2017). Global warming is leading to proliferation and dislocation of mosquito vectors from tropical 
to more temperate zones around the world. With government policies and public health initiatives 
to restrict deforestation, the spread of vector-borne diseases should subside. 
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4.2 Limitations 
This review was limited by the methodology in choosing to build specific database search 
queries around MeSH terms. Relevant, published articles that have not been indexed may have not 
been captured by all database searches. In addition, this review may not be representative to all 
factors contributing to the recent YF outbreak in Brazil that were not published in academic 
journals. Lastly, my inability to read Spanish or Portuguese limited my article findings, thus 
narrowing my search of potentially relevant sources pertaining to my review. 
 37 
5.0 Conclusion 
When considering other infectious diseases, society is fortuitous in the sense there is an 
effective YF vaccine available and it only requires a single dose. Not having to worry about 
multiple doses or reaching people again allows greater accessibility to immunize more people, thus 
increasing coverage. With the reemergence of YF in Brazil, this literature review analyzes the 
contributing challenges in efforts to end the ongoing epidemic in Brazil and points to the need for 
government policy changes regarding vaccinations and deforestation, along with additional vector 
control measures and increased surveillance coverage. As a significant public health concern, this 
poses an unwanted threat to the Brazilian population and wildlife. The Brazilian Ministry of 
Health’s mission is to maintain zero YF incidence cases in urban areas and reduce sylvatic 
incidence in remote areas; however, they are neglecting indirect factors contributing to the spread 
of YF. Efforts to end the epidemic include restricting deforestation, mandating a YF vaccine policy 
for foreign travelers, increasing YF surveillance and vector control measures will in turn assist the 
elimination of YF in Brazil.  Based on the YF seasonal pattern, increased infectivity is expected 
to occur in the next coming months, thus these proposed ideas can be organized into action to 
avoid the development of disease by containing the remaining outbreaks, protecting at-risk 
populations, and preventing further transmission. 
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Appendix: Search Queries 
Table 2. Summary of databases searched 
Table  
Vendor/ 
Interface 
Database 
Date 
searched 
Database update Searcher(s) 
2a 
National 
Library of 
Medicine 
PubMed 
September 
20, 2019 
October 15, 2019 
Elizabeth 
Owens 
2b Ovid Medline® 
October 
16, 2019 
Ovid MEDLINE(R) 
and Epub Ahead of 
Print, In-Process & 
Other Non-Indexed 
Citations and Daily 
1946 to October 7, 
2019 
Elizabeth 
Owens; Helena 
M. VonVille 
2c 
SciELO 
Network 
SciELO 
October 
16, 2019 
October 16, 2019 
Elizabeth 
Owens; Helena 
M. VonVille 
 
Table 2 a. National Library of Medicine search stratgegy 
Provider/Interface National Library of Medicine 
Database PubMed 
Date searched September 20, 2019 
Database update October 15, 2019 
Search developer(s) Elizabeth Owens 
Limit to English  Yes 
Date Range No limits used 
Publication Types No publication types specified 
Search filter source No search filter used 
 
1 Yellow fever and brazil 
 Limits: English 
 
Table 2 b. Medline®  search strategy 
Provider/Interface Ovid 
Database Medline® 
Date searched October 16, 2019 
Database update Ovid MEDLINE(R) and Epub Ahead of Print, 
In-Process & Other Non-Indexed Citations 
and Daily 1946 to October 7, 2019 
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Search developer(s) Elizabeth Owens; Helena M. VonVille 
Limit to English  Yes 
Date Range No limits used 
Publication Types No publication types specified 
Search filter source No search filter used 
 
1. 
vaccines/ or viral vaccines/ or immunization/ or immunization schedule/ or 
immunization, secondary/ or immunotherapy/ or immunotherapy, active/ or 
vaccination/ or mass vaccination/ or immunization programs/ or (vaccin* or immuniz* 
or immunis*).ti,ab,kw. 
2. Yellow Fever/ 
3. Yellow Fever*.ti,ab,kw. 
4. Yellow fever virus/ 
5. 2 or 3 or 4 
6. 1 and 5 
7. yellow fever vaccine/ 
8. 6 or 7 
9. supply chain*.ti,ab,kw. and 8 
10. supply chain*.ti,ab,kw. and 1 
11. limit 10 to english language 
12. 
south america/ or argentina/ or bolivia/ or brazil/ or chile/ or colombia/ or ecuador/ or 
french guiana/ or guyana/ or paraguay/ or peru/ or suriname/ or uruguay/ or venezuela/ 
13. 
(south america or argentina or bolivia or brazil or chile or colombia or ecuador or 
french guiana or guyana or paraguay or peru or suriname or uruguay or 
venezuela).ti,ab,kw. 
14. 12 or 13 
15. 11 and 14 
16. 11 not 15 
17. (barrier* or challenge* or facillitat*).ti,ab,kw. 
18. 1 and 17 
19. 14 and 18 
20. limit 19 to english language 
21. 8 and 20 
22. Mosquito Control/ 
23. culicidae/ or aedes/ or anopheles/ 
24. (culicidae or aedes or mosquito*).ti,ab,kw. 
25. 22 or 23 or 24 
26. 14 and 25 
27. 17 and 26 
28. limit 27 to english language 
29. 8 and 28 
30. Population Density/ 
31. Urban Health/ or Urban Population/ or Urban Health Services/ 
32. Rural Health/ or Rural Population/ or Rural Health Services/ 
33. (rural or urban or population density).ti,ab,kw. 
Table 2b Continued 
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34.  
35. 8 and 25 and 34 
36. 35 and (brazil/ or brazil*.ti,ab,kw.) 
 
Table 2 c. SciELO searach strategy 
Provider/Interface SciELO Network 
Database SciELO 
Date searched October 16, 2019 
Database update October 16, 2019 
Search developer(s) Elizabeth Owens; Helena M. VonVille 
Limit to English  Yes 
Date Range No limits used 
Publication Types No publication types specified 
Search filter source No search filter used 
 
1 yellow fever and brazil 
 Limits: English 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2b Continued 
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